Department of Obstetrics and Gynecology, Sainte-Justine Hospital Research Center, University of Montreal, Montreal, Canada.
Bureau d'information et d'études en santé des populations, Institut national de santé publique du Québec, Montreal, Canada.
Hum Reprod. 2021 Jan 1;36(1):219-228. doi: 10.1093/humrep/deaa270.
Does publicly funded assisted reproductive technology result in improved maternal and infant outcomes?
Publicly funded ART in Quebec was associated with reduced risks of preeclampsia, cesarean delivery, preterm birth, low birth weight and other adverse outcomes.
Publicly funded ART programs that provide free access to single embryo transfer are known to decrease the rate of multiple pregnancy, but the impact on other pregnancy outcomes is unknown.
STUDY DESIGN, SIZE, DURATION: We conducted a pre- and post-comparison study of 597 416 pregnancies conceived between July 2008 and September 2015 in Quebec, Canada, a region where public funding of ART began in August 2010.
PARTICIPANTS/MATERIALS, SETTING, METHODS: We included all pregnant women who conceived by ART (n = 14 309) or spontaneously (n = 583 107) and delivered a live or stillborn infant in hospitals of Quebec. The main exposure measure was conception before versus during the publicly funded ART program. Outcomes included measures of maternal and infant morbidity and mortality. We estimated risk ratios (RR) and 95% confidence intervals for the association of publicly funded ART with maternal and infant outcomes using log-binomial regression models adjusted for maternal characteristics.
In this study, 2638 pregnancies were conceived by ART before, and 11 671 were conceived by ART, during public funding. Compared with no public funding, ART funding was associated with reduced risks of severe maternal morbidity (RR 0.64, 95% CI 0.50-0.83), preeclampsia (RR 0.55, 95% CI 0.44-0.68), cesarean delivery (RR 0.83, 95% CI 0.77-0.89), preterm birth (RR 0.67, 95% CI 0.60-0.75), low birth weight (RR 0.63, 95% CI 0.55-0.72), severe neonatal morbidity (RR 0.75, 95% CI 0.57-0.99) and neonatal intensive care unit admission (RR 0.65, 95% CI 0.53-0.78). When multiple pregnancies were excluded, ART funding continued to be associated with a lower risk of preeclampsia (RR 0.61, 95% CI 0.48-0.79) and preterm birth (RR 0.85, 95% CI 0.73-0.99). However, ART funding was associated with increased risk of gestational diabetes.
LIMITATIONS, REASONS FOR CAUTION: We had no information on the type of ART, number of in-vitro fertilization cycles or number of embryos transferred. We lacked data on body mass index, ethnicity and smoking and cannot rule out residual confounding.
Our findings suggest that publicly funded ART programs that encourage single embryo transfer may have substantial benefits for a range of maternal and infant outcomes, beyond prevention of multiple births.
STUDY FUNDING/COMPETING INTEREST(S): This study was supported by grant 6D02363004 from the Public Health Agency of Canada. N.A. acknowledges a career award from the Fonds de recherche du Québec-Santé (34695). The authors declare no competing interests.
N/A.
公共资助的辅助生殖技术是否会改善母婴结局?
魁北克的公共资助 ART 与子痫前期、剖宫产、早产、低出生体重和其他不良结局的风险降低相关。
众所周知,提供免费单胚胎移植的公共资助 ART 项目可以降低多胎妊娠的发生率,但对其他妊娠结局的影响尚不清楚。
研究设计、大小和持续时间:我们对 2008 年 7 月至 2015 年 9 月期间在加拿大魁北克进行的 597416 例妊娠进行了一项前后比较研究,该地区的公共资助 ART 项目于 2010 年 8 月开始。
参与者/材料、设置、方法:我们纳入了所有通过 ART(n=14309)或自然受孕(n=583107)并在魁北克医院分娩活产或死产婴儿的孕妇。主要暴露测量是受孕时是否处于公共资助 ART 项目之前或期间。结局包括母婴发病率和死亡率的衡量标准。我们使用对数二项式回归模型估计了公共资助 ART 与母婴结局之间的关联的风险比(RR)和 95%置信区间,该模型调整了产妇特征。
在这项研究中,2638 例妊娠是在公共资助之前通过 ART 受孕的,11671 例妊娠是在公共资助期间通过 ART 受孕的。与没有公共资助相比,ART 资助与严重产妇发病率降低相关(RR 0.64,95%CI 0.50-0.83)、子痫前期(RR 0.55,95%CI 0.44-0.68)、剖宫产(RR 0.83,95%CI 0.77-0.89)、早产(RR 0.67,95%CI 0.60-0.75)、低出生体重(RR 0.63,95%CI 0.55-0.72)、严重新生儿发病率(RR 0.75,95%CI 0.57-0.99)和新生儿重症监护病房入院率(RR 0.65,95%CI 0.53-0.78)。当排除多胎妊娠时,ART 资助继续与子痫前期(RR 0.61,95%CI 0.48-0.79)和早产(RR 0.85,95%CI 0.73-0.99)的风险降低相关。
然而,ART 资助与妊娠期糖尿病的风险增加相关。
局限性、谨慎的原因:我们没有关于 ART 类型、体外受精周期数量或胚胎移植数量的信息。我们缺乏关于体重指数、种族和吸烟的数据,不能排除残留混杂。
我们的研究结果表明,鼓励单胚胎移植的公共资助 ART 项目可能会对一系列母婴结局产生重大益处,超出了预防多胎妊娠的范围。
研究资助/利益冲突:本研究得到了加拿大公共卫生局 6D02363004 号赠款的支持。N.A. 得到了魁北克健康研究基金会(34695)的职业奖励。作者没有利益冲突。
无。